UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Portfolio Pulse from Benzinga Newsdesk
UNITY Biotechnology announced results from Part B of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD). The drug demonstrated a favorable safety profile and patients maintained vision gains. The company is now directing resources towards the DME program, where UBX1325 showed significant improvement in visual acuity. A Phase 2b study in patients with diabetic macular edema is expected to start in Q4 2023.
September 27, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UNITY Biotechnology's UBX1325 showed positive results in a Phase 2 study for AMD patients. The company is now focusing on the DME program, with a Phase 2b study expected to start in Q4 2023.
The positive results from the Phase 2 study of UBX1325 are likely to boost investor confidence in UNITY Biotechnology. The company's decision to focus on the DME program, where UBX1325 has shown significant improvement, could also be seen as a positive move. The initiation of a Phase 2b study in Q4 2023 indicates progress in the company's pipeline, which could further support the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100